Alkem Laboratories Limited Net Assets
Alkem Laboratories Limited net assets. Based on the latest financial reports, Alkem Laboratories Limited (ALKEM) has net assets worth Rs138.11 Billion INR (≈ $1.49 Billion USD) as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (Rs202.87 Billion ≈ $2.19 Billion USD) and total liabilities (Rs64.77 Billion ≈ $700.41 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Also explore net asset growth rate of Alkem Laboratories Limited to track the company's year-over-year net asset growth rate.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | Rs138.11 Billion |
| % of Total Assets | 68.08% |
| Annual Growth Rate | 16.83% |
| 5-Year Change | 64.51% |
| 10-Year Change | 228.33% |
| Growth Volatility | 13.93 |
Net Assets of Alkem Laboratories Limited (2010–2025)
Net assets of Alkem Laboratories Limited from 2010 to 2025. This chart illustrates how Alkem Laboratories Limited's net assets have evolved over time, based on quarterly financial data. See how leveraged is Alkem Laboratories Limited's balance sheet to measure how much of total assets are equity-financed.
Annual Net Assets for Alkem Laboratories Limited (2010–2025)
The table below shows the annual net assets of Alkem Laboratories Limited from 2010 to 2025. For live market cap and overall valuation, see ALKEM stock market capitalisation.
| Year | Net Assets | Change |
|---|---|---|
| 2025-03-31 | Rs124.34 Billion ≈ $1.34 Billion |
+16.05% |
| 2024-03-31 | Rs107.14 Billion ≈ $1.16 Billion |
+13.56% |
| 2023-03-31 | Rs94.35 Billion ≈ $1.02 Billion |
+6.64% |
| 2022-03-31 | Rs88.47 Billion ≈ $956.81 Million |
+17.06% |
| 2021-03-31 | Rs75.58 Billion ≈ $817.37 Million |
+19.80% |
| 2020-03-31 | Rs63.09 Billion ≈ $682.29 Million |
+13.23% |
| 2019-03-31 | Rs55.72 Billion ≈ $602.59 Million |
+11.77% |
| 2018-03-31 | Rs49.85 Billion ≈ $539.14 Million |
+8.78% |
| 2017-03-31 | Rs45.83 Billion ≈ $495.62 Million |
+21.02% |
| 2016-03-31 | Rs37.87 Billion ≈ $409.55 Million |
+22.77% |
| 2015-03-31 | Rs30.85 Billion ≈ $333.60 Million |
+16.18% |
| 2014-03-31 | Rs26.55 Billion ≈ $287.14 Million |
+11.85% |
| 2013-03-31 | Rs23.74 Billion ≈ $256.72 Million |
+24.58% |
| 2012-03-31 | Rs19.06 Billion ≈ $206.08 Million |
+63.22% |
| 2011-03-31 | Rs11.67 Billion ≈ $126.25 Million |
-3.14% |
| 2010-03-31 | Rs12.05 Billion ≈ $130.35 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Alkem Laboratories Limited's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 10641.3% over the analyzed period, indicating profitable operations and earnings retention.
Alkem Laboratories Limited Net Assets Breakdown (March 2025)
Alkem Laboratories Limited net assets breakdown by equity component as of March 2025.
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | Rs99.73 Billion | 83.21% |
| Common Stock | Rs239.10 Million | 0.20% |
| Other Comprehensive Income | Rs19.88 Billion | 16.59% |
| Total Equity | Rs119.85 Billion | 100.00% |
Alkem Laboratories Limited Competitors by Market Cap
The table below lists competitors of Alkem Laboratories Limited ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Artemis Gold Inc
V:ARTG
|
$6.85 Billion |
|
Yanzhou Coal Mining Company Limited
F:YZC
|
$6.86 Billion |
|
BlueFocus Communication Group
SHE:300058
|
$6.86 Billion |
|
Birkenstock Holding plc
NYSE:BIRK
|
$6.86 Billion |
|
ZEEKR Intelligent Technology Holding Limited
NYSE:ZK
|
$6.85 Billion |
|
Tripod Technology Corp
TW:3044
|
$6.85 Billion |
|
Adani Total Gas Limited
NSE:ATGL
|
$6.84 Billion |
|
Shanghai Pharmaceuticals Holding Co Ltd
SHG:601607
|
$6.84 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Alkem Laboratories Limited's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 103,120,600,000 to 119,848,700,000, a change of 16,728,100,000 (16.2%).
- Net income of 21,654,800,000 contributed positively to equity growth.
- Dividend payments of 5,046,200,000 reduced retained earnings.
- Other comprehensive income increased equity by 95,000,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | Rs21.65 Billion | +18.07% |
| Dividends Paid | Rs5.05 Billion | -4.21% |
| Other Comprehensive Income | Rs95.00 Million | +0.08% |
| Other Changes | Rs24.50 Million | +0.02% |
| Total Change | Rs- | 16.22% |
Book Value vs Market Value Analysis
This analysis compares Alkem Laboratories Limited's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 5.28x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 52.55x to 5.28x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2010-03-31 | Rs100.80 | Rs5297.00 | x |
| 2011-03-31 | Rs119.39 | Rs5297.00 | x |
| 2012-03-31 | Rs159.37 | Rs5297.00 | x |
| 2013-03-31 | Rs198.54 | Rs5297.00 | x |
| 2014-03-31 | Rs222.06 | Rs5297.00 | x |
| 2015-03-31 | Rs250.83 | Rs5297.00 | x |
| 2016-03-31 | Rs308.78 | Rs5297.00 | x |
| 2017-03-31 | Rs373.66 | Rs5297.00 | x |
| 2018-03-31 | Rs406.79 | Rs5297.00 | x |
| 2019-03-31 | Rs454.93 | Rs5297.00 | x |
| 2020-03-31 | Rs515.26 | Rs5297.00 | x |
| 2021-03-31 | Rs616.96 | Rs5297.00 | x |
| 2022-03-31 | Rs722.44 | Rs5297.00 | x |
| 2023-03-31 | Rs756.52 | Rs5297.00 | x |
| 2024-03-31 | Rs862.46 | Rs5297.00 | x |
| 2025-03-31 | Rs1002.36 | Rs5297.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Alkem Laboratories Limited utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 18.07%
- The company demonstrates strong efficiency in generating profits from shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 16.91%
- • Asset Turnover: 0.72x
- • Equity Multiplier: 1.48x
- Recent ROE (18.07%) is above the historical average (17.95%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2010 | 19.50% | 17.49% | 0.86x | 1.29x | Rs1.15 Billion |
| 2011 | 22.66% | 19.57% | 0.64x | 1.81x | Rs1.81 Billion |
| 2012 | 22.33% | 22.17% | 0.60x | 1.67x | Rs2.35 Billion |
| 2013 | 20.90% | 21.79% | 0.56x | 1.71x | Rs2.59 Billion |
| 2014 | 16.53% | 14.27% | 0.71x | 1.64x | Rs1.73 Billion |
| 2015 | 13.06% | 10.55% | 0.70x | 1.77x | Rs916.85 Million |
| 2016 | 20.09% | 15.24% | 0.88x | 1.50x | Rs3.72 Billion |
| 2017 | 19.97% | 15.88% | 0.86x | 1.47x | Rs4.45 Billion |
| 2018 | 12.97% | 10.01% | 0.82x | 1.58x | Rs1.45 Billion |
| 2019 | 13.98% | 10.47% | 0.89x | 1.51x | Rs2.17 Billion |
| 2020 | 18.29% | 13.76% | 0.82x | 1.61x | Rs5.11 Billion |
| 2021 | 21.49% | 18.16% | 0.76x | 1.56x | Rs8.47 Billion |
| 2022 | 19.05% | 15.65% | 0.75x | 1.63x | Rs7.82 Billion |
| 2023 | 10.88% | 8.60% | 0.83x | 1.52x | Rs796.41 Million |
| 2024 | 17.41% | 14.44% | 0.80x | 1.51x | Rs7.65 Billion |
| 2025 | 18.07% | 16.91% | 0.72x | 1.48x | Rs9.67 Billion |
Industry Comparison
This section compares Alkem Laboratories Limited's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $14,900,234,315
- Average return on equity (ROE) among peers: 18.08%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Alkem Laboratories Limited (ALKEM) | Rs138.11 Billion | 19.50% | 0.47x | $6.85 Billion |
| Aarey Drugs & Pharmaceuticals Limited (AAREYDRUGS) | $923.46 Million | 6.27% | 1.10x | $33.03 Million |
| Aarti Drugs Limited (AARTIDRUGS) | $2.51 Billion | 24.60% | 2.39x | $440.96 Million |
| Aarti Pharmalabs Limited (AARTIPHARM) | $19.90 Billion | 13.69% | 0.46x | $910.81 Million |
| Abbott India Limited (ABBOTINDIA) | $6.47 Billion | 22.37% | 0.40x | $6.05 Billion |
| Ajanta Pharma Limited (AJANTPHARM) | $1.57 Billion | 16.19% | 1.95x | $4.47 Billion |
| Akums Drugs and Pharmaceutical (AKUMS) | $30.64 Billion | 11.04% | 0.34x | $1.22 Billion |
| Amrutanjan Health Care Limited (AMRUTANJAN) | $964.67 Million | 9.99% | 0.49x | $160.79 Million |
| Alembic Pharmaceuticals Limited (APLLTD) | $2.95 Billion | 28.92% | 1.86x | $2.05 Billion |
| Aurobindo Pharma Limited (AUROPHARMA) | $68.18 Billion | 29.70% | 1.34x | $11.20 Billion |
About Alkem Laboratories Limited
Alkem Laboratories Limited, a pharmaceutical company, engages in the research and development, manufacture, and sale of pharmaceutical and nutraceutical products in India, the United States, and internationally. The company offers branded generics, generic drugs, active pharmaceutical ingredients, and biosimilars, and nutraceuticals in acute and chronic therapeutic areas comprising anti-infective… Read more